{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T01:47:28Z","timestamp":1782092848717,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN-148390"],"award-info":[{"award-number":["FDN-148390"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"DOI":"10.1038\/s41523-026-00955-8","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:54:04Z","timestamp":1776772444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multimodal analysis of a rare BARD1 missense variant suggests its pathogenicity is conditional"],"prefix":"10.1038","volume":"12","author":[{"given":"Fiona","family":"Chan-Pak-Choon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuandi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Camacho-Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia-Ji\u00e9","family":"Cabr\u00e9-Romans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amisha","family":"Minju-OP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paz","family":"Polak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Cuella-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7427-4651","authenticated-orcid":false,"given":"William D.","family":"Foulkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"955_CR1","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z","volume":"77","author":"EB Claus","year":"1996","unstructured":"Claus, E. B., Schildkraut, J. M., Thompson, W. D. & Risch, N. J. The genetic attributable risk of breast and ovarian cancer. Cancer 77, 2318\u20132324 (1996).","journal-title":"Cancer"},{"key":"955_CR2","doi-asserted-by":"publisher","first-page":"E1175","DOI":"10.1002\/humu.21200","volume":"31","author":"S De Brakeleer","year":"2010","unstructured":"De Brakeleer, S. et al. Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families. Hum. Mutat. 31, E1175\u2013E1185 (2010).","journal-title":"Hum. Mutat."},{"key":"955_CR3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.annonc.2025.04.012","volume":"36","author":"C Turnbull","year":"2025","unstructured":"Turnbull, C. et al. Breast cancer germline multigene panel testing in mainstream oncology based on clinical-public health utility: ESMO Precision Oncology Working Group recommendations. Ann. Oncol. 36, 853\u2013865 (2025).","journal-title":"Ann. Oncol."},{"key":"955_CR4","doi-asserted-by":"crossref","unstructured":"Breast Cancer Association Consortium. Breast cancer risk genes \u2014 association analysis in more than 113,000 women. N. Engl. J. Med. 384, 428-439, (2021).","DOI":"10.1056\/NEJMoa1913948"},{"key":"955_CR5","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"384","author":"C Hu","year":"2021","unstructured":"Hu, C. et al. A population-based study of genes previously implicated in breast cancer. N. Engl. J. Med. 384, 440\u2013451 (2021).","journal-title":"N. Engl. J. Med."},{"key":"955_CR6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41571-021-00491-3","volume":"18","author":"WD Foulkes","year":"2021","unstructured":"Foulkes, W. D. The ten genes for breast (and ovarian) cancer susceptibility. Nat. Rev. Clin. Oncol. 18, 259\u2013260 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"955_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/his.14808","volume":"82","author":"A Sokolova","year":"2023","unstructured":"Sokolova, A., Johnstone, K. J., McCart Reed, A. E., Simpson, P. T. & Lakhani, S. R. Hereditary breast cancer: syndromes, tumour pathology and molecular testing. Histopathology 82, 70\u201382 (2023).","journal-title":"Histopathology"},{"key":"955_CR8","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41580-020-0218-z","volume":"21","author":"M Tarsounas","year":"2020","unstructured":"Tarsounas, M. & Sung, P. The antitumorigenic roles of BRCA1\u2013BARD1 in DNA repair and replication. Nat. Rev. Mol. Cell Biol. 21, 284\u2013299 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"955_CR9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.tibs.2022.03.001","volume":"47","author":"SR Witus","year":"2022","unstructured":"Witus, S. R., Zhao, W., Brzovic, P. S. & Klevit, R. E. BRCA1\/BARD1 is a nucleosome reader and writer. Trends Biochem. Sci. 47, 582\u2013595 (2022).","journal-title":"Trends Biochem. Sci."},{"key":"955_CR10","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/ng.3934","volume":"49","author":"P Polak","year":"2017","unstructured":"Polak, P. et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat. Genet 49, 1476\u20131486 (2017).","journal-title":"Nat. Genet"},{"key":"955_CR11","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature24060","volume":"550","author":"W Zhao","year":"2017","unstructured":"Zhao, W. et al. BRCA1\u2013BARD1 promotes RAD51-mediated homologous DNA pairing. Nature 550, 360\u2013365 (2017).","journal-title":"Nature"},{"key":"955_CR12","doi-asserted-by":"publisher","first-page":"856","DOI":"10.3390\/genes11080856","volume":"11","author":"WM Alenezi","year":"2020","unstructured":"Alenezi, W. M., Fierheller, C. T., Recio, N. & Tonin, P. N. Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers. Genes 11, 856 (2020).","journal-title":"Genes"},{"key":"955_CR13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/cge.12620","volume":"89","author":"S De Brakeleer","year":"2016","unstructured":"De Brakeleer, S. et al. Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients. Clin. Genet. 89, 336\u2013340 (2016).","journal-title":"Clin. Genet."},{"key":"955_CR14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3390\/genes12020150","volume":"12","author":"P Rofes","year":"2021","unstructured":"Rofes, P. et al. BARD1 pathogenic variants are associated with triple-negative breast cancer in a Spanish hereditary breast and ovarian cancer cohort. Genes 12, 150 (2021).","journal-title":"Genes"},{"key":"955_CR15","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","volume":"3","author":"FJ Couch","year":"2017","unstructured":"Couch, F. J. et al. Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol. 3, 1190\u20131196 (2017).","journal-title":"JAMA Oncol."},{"key":"955_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-017-0024-8","volume":"3","author":"TP Slavin","year":"2017","unstructured":"Slavin, T. P. et al. The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. NPJ Breast Cancer 3, 22 (2017).","journal-title":"NPJ Breast Cancer"},{"key":"955_CR17","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1038\/s41436-018-0005-9","volume":"20","author":"L Cast\u00e9ra","year":"2018","unstructured":"Cast\u00e9ra, L. et al. Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families. Genet Med. 20, 1677\u20131686 (2018).","journal-title":"Genet Med."},{"key":"955_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1137-9","volume":"21","author":"N Weber-Lassalle","year":"2019","unstructured":"Weber-Lassalle, N. et al. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer. Breast Cancer Res. 21, 55 (2019).","journal-title":"Breast Cancer Res."},{"key":"955_CR19","doi-asserted-by":"publisher","unstructured":"Suszynska, M. & Kozlowski, P. Summary of BARD1 mutations and precise estimation of breast and ovarian cancer risks associated with the mutations. Genes 11, https:\/\/doi.org\/10.3390\/genes11070798 (2020).","DOI":"10.3390\/genes11070798"},{"key":"955_CR20","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/jnci\/djy106","volume":"110","author":"H Shimelis","year":"2018","unstructured":"Shimelis, H. et al. Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing. J. Natl. Cancer Inst. 110, 855\u2013862 (2018).","journal-title":"J. Natl. Cancer Inst."},{"key":"955_CR21","doi-asserted-by":"publisher","unstructured":"Toh, M. R. et al. Functional analysis of clinical BARD1 germline variants. Cold Spring Harb. Mol. Case Stud. 5, https:\/\/doi.org\/10.1101\/mcs.a004093 (2019).","DOI":"10.1101\/mcs.a004093"},{"key":"955_CR22","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41586-021-03776-w","volume":"596","author":"JR Becker","year":"2021","unstructured":"Becker, J. R. et al. BARD1 reads H2A lysine 15 ubiquitination to direct homologous recombination. Nature 596, 433\u2013437 (2021).","journal-title":"Nature"},{"key":"955_CR23","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1073\/pnas.1715467115","volume":"115","author":"MD Stewart","year":"2018","unstructured":"Stewart, M. D. et al. BARD1 is necessary for ubiquitylation of nucleosomal histone H2A and for transcriptional regulation of estrogen metabolism genes. Proc. Natl. Acad. Sci. USA 115, 1316\u20131321 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"955_CR24","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/humu.22902","volume":"36","author":"C Lee","year":"2015","unstructured":"Lee, C. et al. Functional analysis of BARD1 missense variants in homology-directed repair of DNA double strand breaks. Hum. Mutat. 36, 1205\u20131214 (2015).","journal-title":"Hum. Mutat."},{"key":"955_CR25","doi-asserted-by":"publisher","first-page":"9379","DOI":"10.1093\/nar\/gkv993","volume":"43","author":"J Pinder","year":"2015","unstructured":"Pinder, J., Salsman, J. & Dellaire, G. Nuclear domain \u2018knock-in\u2019 screen for the evaluation and identification of small molecule enhancers of CRISPR-based genome editing. Nucleic Acids Res. 43, 9379\u20139392 (2015).","journal-title":"Nucleic Acids Res."},{"key":"955_CR26","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1200\/JCO.2011.37.2482","volume":"30","author":"LS Lindstr\u00f6m","year":"2012","unstructured":"Lindstr\u00f6m, L. S. et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J. Clin. Oncol. 30, 2601\u20132608 (2012).","journal-title":"J. Clin. Oncol."},{"key":"955_CR27","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/jnci\/djx273","volume":"110","author":"WAME Schrijver","year":"2018","unstructured":"Schrijver, W. A. M. E. et al. Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis. JNCI J. Natl. Cancer Inst. 110, 568\u2013580 (2018).","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"955_CR28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10549-024-07368-w","volume":"207","author":"L Schwieger","year":"2024","unstructured":"Schwieger, L. et al. Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival. Breast Cancer Res. Treat. 207, 373\u2013382 (2024).","journal-title":"Breast Cancer Res. Treat."},{"key":"955_CR29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10549-024-07431-6","volume":"207","author":"GP Dowling","year":"2024","unstructured":"Dowling, G. P. et al. Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease. Breast Cancer Res. Treat. 207, 471\u2013476 (2024).","journal-title":"Breast Cancer Res. Treat."},{"key":"955_CR30","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1634\/theoncologist.2012-0350","volume":"18","author":"E Curtit","year":"2013","unstructured":"Curtit, E. et al. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Oncologist 18, 667\u2013674 (2013).","journal-title":"Oncologist"},{"key":"955_CR31","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","volume":"21","author":"WJ Gradishar","year":"2023","unstructured":"Gradishar, W. J. et al. NCCN Guidelines\u00ae insights: breast cancer, version 4.2023: featured updates to the NCCN guidelines. J. Natl. Compr. Cancer Netw. 21, 594\u2013608 (2023).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"955_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01428-5","volume":"23","author":"Y Zheng","year":"2021","unstructured":"Zheng, Y. et al. Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient. Breast Cancer Res. 23, 53 (2021).","journal-title":"Breast Cancer Res."},{"key":"955_CR33","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1056\/NEJMc2403316","volume":"391","author":"M Cupit-Link","year":"2024","unstructured":"Cupit-Link, M. et al. Response to PARP inhibition in BARD1-mutated refractory neuroblastoma. N. Engl. J. Med 391, 659\u2013661 (2024).","journal-title":"N. Engl. J. Med"},{"key":"955_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013423 (2015).","journal-title":"Genet. Med."},{"key":"955_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0690-2","volume":"12","author":"SE Brnich","year":"2019","unstructured":"Brnich, S. E. et al. Recommendations for application of the functional evidence PS3\/BS3 criterion using the ACMG\/AMP sequence variant interpretation framework. Genome Med. 12, 3 (2019).","journal-title":"Genome Med."},{"key":"955_CR36","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"955_CR37","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20, 1297\u20131303 (2010).","journal-title":"Genome Res"},{"key":"955_CR38","doi-asserted-by":"publisher","unstructured":"Poplin, R. et al. Scaling accurate genetic variant discovery to tens of thousands of samples. bioRxiv, 201178, https:\/\/doi.org\/10.1101\/201178 (2018).","DOI":"10.1101\/201178"},{"key":"955_CR39","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164\u2013e164 (2010).","journal-title":"Nucleic Acids Res."},{"key":"955_CR40","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nature12981","volume":"505","author":"N Rahman","year":"2014","unstructured":"Rahman, N. Realizing the promise of cancer predisposition genes. Nature 505, 302\u2013308 (2014).","journal-title":"Nature"},{"key":"955_CR41","unstructured":"Illumina. TruSight Cancer Gene List, https:\/\/www.illumina.com\/content\/dam\/illumina-marketing\/documents\/products\/gene_lists\/gene_list_trusight_cancer.xlsx."},{"key":"955_CR42","unstructured":"Invitae. Invitae Multi-Cancer Panel, https:\/\/www.invitae.com\/en\/providers\/test-catalog\/test-01101."},{"key":"955_CR43","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2018","unstructured":"Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941\u2013D947 (2018).","journal-title":"Nucleic Acids Res."},{"key":"955_CR44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/annonc\/mdu479","volume":"26","author":"F Favero","year":"2015","unstructured":"Favero, F. et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann. Oncol. 26, 64\u201370 (2015).","journal-title":"Ann. Oncol."},{"key":"955_CR45","doi-asserted-by":"publisher","unstructured":"Liu, M. et al. MesKit: a tool kit for dissecting cancer evolution of multi-region tumor biopsies through somatic alterations. GigaScience 10, https:\/\/doi.org\/10.1093\/gigascience\/giab036 (2021).","DOI":"10.1093\/gigascience\/giab036"},{"key":"955_CR46","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94\u2013101 (2020).","journal-title":"Nature"},{"key":"955_CR47","doi-asserted-by":"publisher","first-page":"e6529","DOI":"10.1371\/journal.pone.0006529","volume":"4","author":"E Campeau","year":"2009","unstructured":"Campeau, E. et al. A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One 4, e6529 (2009).","journal-title":"PLoS One"},{"key":"955_CR48","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/s41588-025-02308-w","volume":"57","author":"K K\u00fcbler","year":"2025","unstructured":"K\u00fcbler, K. et al. Tamoxifen induces PI3K activation in uterine cancer. Nat. Genet. 57, 2192\u20132202 (2025).","journal-title":"Nat. Genet."}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00955-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00955-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00955-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T01:03:38Z","timestamp":1782090218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00955-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["955"],"URL":"https:\/\/doi.org\/10.1038\/s41523-026-00955-8","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}